Journal profile · Endocrinology & Metabolism
Diabetes Technology & Therapeutics
ISSN 1520-9156 · eISSN 1557-8593 · Mary Ann Liebert Inc. · UNITED STATES · Monthly · Founded 1999
Diabetes Technology & Therapeutics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 7.3; hybrid open access; review 3–8 weeks (community reports); community-reported acceptance: easy; 216 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Diabetes Technology & Therapeutics is published by Mary Ann Liebert Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Management and Research, Pancreatic function and diabetes and Diabetes and associated disorders, together about 55.7% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
Source: LetPub
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief Satish K GargPublisher website
Editorial board by country: none in mainland China; most named United States 14, United Kingdom 5, Germany 2, Australia 2, India 1 (32 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Management and ResearchMedicine31.2%
- Pancreatic function and diabetesMedicine12.8%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology11.7%
- Hyperglycemia and glycemic control in critically ill and hospitalized patientsMedicine11.5%
- Diabetes Treatment and ManagementMedicine7.8%
- Diabetes Management and EducationMedicine4.3%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine4.2%
- Mobile Health and mHealth ApplicationsHealth Professions3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.3LetPub ·
- Impact factor (publisher)
- 7.4Publisher website ·
- 5-year impact factor (publisher)
- 5.8Publisher website ·
- CiteScore 2026-06
- 10.5LetPub ·
- SJR 2026-06
- 2.66LetPub ·
- SNIP 2026-06
- 1.73LetPub ·
- h-index
- 79LetPub ·
- h-index
- 131OpenAlex ·
- i10-index
- 2,257OpenAlex ·
- 2-year mean citedness
- 5.46OpenAlex ·
- Self-citation rate
- 18.9%LetPub ·
- Share of gold OA articles
- 23.73%LetPub ·
Volume
- Articles per year
- 160LetPub ·
Articles by year OpenAlex count · 3,929 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 163 | 24 | 105 |
| 2025 | 216 | 104 | 787 |
| 2024 | 157 | 81 | 2,032 |
| 2023 | 149 | 53 | 3,007 |
| 2022 | 132 | 55 | 2,472 |
| 2021 | 165 | 85 | 3,848 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1999
- ISSN
- 1520-9156
- Electronic ISSN
- 1557-8593
- Latest issue on the website
- Volume 28, Issue 8 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Diabetes Technology & Therapeutics
What CAS zone is Diabetes Technology & Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Diabetes Technology & Therapeutics is in Zone 2 of Medicine, and in Zone 2 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Diabetes Technology & Therapeutics?
The latest impact factor listed by LetPub is 7.3; CiteScore 10.5, h-index 131.
How long does peer review take at Diabetes Technology & Therapeutics?
Authors report an average review time of 3–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Diabetes Technology & Therapeutics based?
Of the 32 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (14), United Kingdom (5) and Germany (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Diabetes Technology & Therapeutics?
According to LetPub and DOAJ records, Diabetes Technology & Therapeutics is indexed in SCIE and Scopus.
Is Diabetes Technology & Therapeutics open access, and what is the APC?
Diabetes Technology & Therapeutics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .